Apellis drops as disappointing Syfovre sales drive Q3 miss
Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...
FiercePharma5d
Analysts point to Syfovre 'nadir' after Apellis discloses disappointing quarter
Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...
Apellis Pharmaceuticals: Long-Term Growth Potential for Syfovre Despite Short-Term Sales Challenges
Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...
Mena FN6d
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
Apellis is well positioned for future growth. We remain confident in our long-term strategy and the significant opportunities ahead.” Generated $152.0 million in SYFOVRE U.S. net product revenue ...
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
Shares of Apellis Pharmaceuticals ( APLS 2.47%) are down by about 62% from the peak they reached in January. However, investment bank analysts who follow the drugmaker think its best days are still ...